Inhalable ivermectin-loaded lipid-polymer hybrid nanoparticles as a promising anticancer platform for non-small cell lung cancer

Pulmonary drug delivery offers a compelling strategy for lung diseases including lung cancer, which remains the leading cause of cancer-related mortalities worldwide, by enabling direct tumour site targeting, avoidance of first-pass metabolism, and high local drug concentrations with reduced systemic toxicity. In this study, inhalable ivermectin-loaded lipid–polymer hybrid nanoparticles (IVM-LPHNPs) were investigated in A549 and H460 non-small cell lung cancer cell lines (NSCLC). Cellular uptake was examined by confocal microscopy and flow cytometry, while in vitro therapeutic efficacy was evaluated through cell viability, wound healing, and colony formation assays to determine their anticancer, anti-proliferative, anti-migratory, and anti-clonogenic activities. Cellular uptake analysis confirmed improved intracellular accumulation of coumarin-6 loaded -LPHNPs relative to free coumarin-6. Moreover, IVM-LPHNPs demonstrated approximately 20% reduction in IC50 compared to free ivermectin, while blank LPHNPs did not reduce viability. Developed formulations showed no considerable toxicity to human bronchial epithelial cells, confirming the safety of LPHNPs for healthy lung cells. Furthermore, more than 50% reduction in clonogenic survival and significantly greater inhibition of cell proliferation and migration was observed in IVM-loaded LPHNPs compared to free IVM. Collectively, these findings position IVM-LPHNPs as a promising inhalable platform for the localized treatment of NSCLC, warranting further investigation in preclinical models.

Authors

Institutions

Publication Details

Journal
Artificial Cells Nanomedicine and Biotechnology
Published
2026-11-12
DOI
https://doi.org/10.1080/21691401.2026.2761354
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhalable ivermectin-loaded lipid-polymer hybrid nanoparticles as a promising anticancer platform for non-small cell lung cancer

Nazrul Islam, Godwin Adefikayo Ayoko, Derek J. Richard, Seyedeh Negin Kassaee
Artificial Cells Nanomedicine and Biotechnology
Nanoparticle-Based Drug Delivery
article

Inhalable ivermectin-loaded lipid-polymer hybrid nanoparticles as a promising anticancer platform for non-small cell lung cancer

Nazrul Islam, Godwin Adefikayo Ayoko, Derek J. Richard, Seyedeh Negin Kassaee
article en

Abstract

Pulmonary drug delivery offers a compelling strategy for lung diseases including lung cancer, which remains the leading cause of cancer-related mortalities worldwide, by enabling direct tumour site targeting, avoidance of first-pass metabolism, and high local drug concentrations with reduced systemic toxicity. In this study, inhalable ivermectin-loaded lipid–polymer hybrid nanoparticles (IVM-LPHNPs) were investigated in A549 and H460 non-small cell lung cancer cell lines (NSCLC). Cellular uptake was examined by confocal microscopy and flow cytometry, while in vitro therapeutic efficacy was evaluated through cell viability, wound healing, and colony formation assays to determine their anticancer, anti-proliferative, anti-migratory, and anti-clonogenic activities. Cellular uptake analysis confirmed improved intracellular accumulation of coumarin-6 loaded -LPHNPs relative to free coumarin-6. Moreover, IVM-LPHNPs demonstrated approximately 20% reduction in IC50 compared to free ivermectin, while blank LPHNPs did not reduce viability. Developed formulations showed no considerable toxicity to human bronchial epithelial cells, confirming the safety of LPHNPs for healthy lung cells. Furthermore, more than 50% reduction in clonogenic survival and significantly greater inhibition of cell proliferation and migration was observed in IVM-loaded LPHNPs compared to free IVM. Collectively, these findings position IVM-LPHNPs as a promising inhalable platform for the localized treatment of NSCLC, warranting further investigation in preclinical models.

Artificial Cells Nanomedicine and BiotechnologyVol. 54(1)
Queensland University of Technology (AU)
Queensland University of Technology, Institute for Future Environments, Queensland University of Technology
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon